Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis Delta and 96 weeks of posttreatment follow-up
View Full Paper
Ask AI
Bookmark
Share
Key Points
Bulevirtide treatment demonstrated sustained efficacy and safety up to 144 weeks for chronic hepatitis delta.
Patients undergoing bulevirtide monotherapy had consistent results throughout the 144-week observation period.
Phase 3 study employed randomised methods to rigorously assess bulevirtide's impact on chronic hepatitis delta.
The findings support bulevirtide as a viable long-term treatment option, indicating its potential in clinical practice.
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Randomised phase 3 study evaluated efficacy and safety of bulevirtide in chronic hepatitis delta, revealing long-term benefits.